Andrew Combs - Feb 7, 2023 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
EVP, Head of Chemistry
Signature
/s/ Laurent Chardonnet, Attorney-in-Fact
Stock symbol
PRLD
Transactions as of
Feb 7, 2023
Transactions value $
$0
Form type
4
Date filed
2/9/2023, 03:08 PM
Previous filing
Apr 4, 2022
Next filing
Mar 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Employee Stock Option (right to buy) Award $0 +135K $0.00 135K Feb 7, 2023 Common Stock 135K $7.20 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on February 7, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.